EP3821912
RPGR GENAMEÐFERÐ VIÐ SJÓNUFREKNUM
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.7.2015EP published:
12.6.2024EP application number:
20199208.8
EP translation filed:
31.7.2024Grant published:
15.9.2024EPO information:
European Patent Register
Max expiry date:
16.7.2035Expiry date:
16.7.2026Next due date:
31.7.2026
Title in English:
RPGR GENE THERAPY FOR RETINITIS PIGMENTOSALanguage of the patent:
English
Timeline
Today
17.7.2015EP application
12.6.2024EP Publication
31.7.2024Translation submitted
15.9.2024Registration published
16.7.2026Expires
Owner
Name:
Massachusetts Eye & Ear InfirmaryAddress:
243 Charles Street, Boston, MA 02114, US
Name:
UCL Business LtdAddress:
University College London Gower Street, London WC1E 6BT, GB
Name:
The Government of the United States of America as represented by the Secretary, Department of Health and Human ServicesAddress:
The Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard Suite 325, MSC 7660, Bethesda, MD 20892-7660, US
Inventor
Name:
SANDBERG, Michael AAddress:
Reading, MA 01867, US
Name:
PAWLYK, BasilAddress:
Hampton Falls, NH 03844, US
Name:
LI, TiansenAddress:
Clarksburg, MD 20871, US
Name:
SHU, XinhuaAddress:
Glasgow, G76 7XY, GB
Name:
WRIGHT, Alan FinlayAddress:
Edinburgh, EH13 0BN, GB
Name:
ALI, RobinAddress:
Clarksburg, MD 20871, US
Agent
Name:
Zacco Denmark A/SAddress:
Arne Jacobsens Allé 15, DK
Priority
Number:
201462028638 PDate:
24.7.2014Country:
US
Classification
Categories:
A61K 48/00, C12N 15/861
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 23.9.2024
Expires: 16.7.2025
Payer: Árnason Faktor ehf.
Number: 11
Paid: 9.7.2025
Expires: 16.7.2026
Payer: Árnason Faktor ehf.